About RMI - more information

RusnanoMedInvest (RMI, subsidiary of RUSNANO JSC ) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. RMI was created in March 2012.

The key strategic objective RusnanoMedInvest is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in  Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.

RusnanoMedInvest manages the companies dealing with development of innovative products in pharmaceutical industry, biotechnology field and medical facilities, including management through participation in their board of directors, and conducts research in the field of innovative products in pharmaceutical industry, biotechnology field and medical facilities.

Together with the well-known U.S. life sciences venture firm Domain Associates LLC, RusnanoMedInvest is now evaluating a wide range of life sciences and pharmaceuticals investment opportunities with a view to investing in approximately 20 promising technologies and localizing these technologies in Russia.